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ABSTRACT 
Background: Several studies have suggested that proton-pump inhibitors (PPIs), mostly 
omeprazole, interact with clopidogrel efficacy by inhibiting the formation of its active 
metabolite via CYP2C19 inhibition. Whether this occurs with all PPIs remains however, a 
matter of debate. Since rabeprazole is a less potent CYP2C19 inhibitor than other PPIs, we 
studied the interaction between rabeprazole and the antiplatelet actions and pharmacokinetics of 
clopidogrel.   
Aims: Primary objective was to demonstrate non-inferiority of rabeprazole over placebo using 
the change in platelet reactivity index (VAsodilator-Stimulated Phosphoprotein, VASP assay) in 
the predefined population of clopidogrel good responders. Omeprazole was used as the positive 
control. 
Methods: Randomized, 3-period cross-over study in healthy volunteers. Thirty six healthy male 
subjects received clopidogrel (75mg/day for 7 days) together with placebo, omeprazole 
(20mg/day) or rabeprazole (20mg/day). Clopidogrel antiplatelet effect and disposition kinetics 
were assessed on day 7 of combination therapy. Non-inferiority threshold was predefined as an 
upper limit of the 90% CI for the difference of change in platelet reactivity index between 
placebo and rabeprazole <10% in good clopidogrel responders. 
Results: In the predefined group of good clopidogrel responders (inhibition of VASP index 
>30%), clopidogrel antiplatelet effect remained non-inferior to placebo during rabeprazole 
(difference 3.4% (-1.7, 8.5)) but not during omeprazole co-administration (difference 7.5% (2.5, 
12.6)). AUC0-24 and Cmax of active clopidogrel metabolite decreased with both omeprazole and 
rabeprazole and conditions of bioequivalence were not met except for AUC0-24 with rabeprazole. 
Conclusion: Rabeprazole does not interact with clopidogrel to the same extent as omeprazole 
does. However, under our experimental conditions and proton-pump inhibitors doses, there was 
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no significant pharmacodynamic interaction between rabeprazole and clopidogrel despite a 
significant decrease in the formation of clopidogrel active metabolite. 
Clinical Trial Registry n° NCT00989300 
Key Words (MeSH): Clopidogrel; CYP2C19 protein, human; Cytochrome P-450 Enzyme 
System; Drug Interactions; Proton Pump Inhibitors; Vasodilator-stimulated Phosphoprotein 
 3
RÉSUMÉ 
Justification. Plusieurs études, principalement menées avec l’oméprazole, ont suggéré une 
interaction entre inhibiteurs de la pompe à protons (IPPs) et clopidogrel, via l’inhibition du 
CYP2C19 impliqué dans la transformation de la pro-drogue clopidogrel en metabolite actif. 
L’importance de cette interaction avec les autres inhibiteurs de pompes à protons est discutée. 
Cette étude avait pour objectif l’analyse de l’interaction pharmacodynamique et 
pharmacocinétique entre le rabéprazole, un inhibiteur plus faible du CYP2C19 que 
l’oméprazole, et le clopidogrel.  
Objectifs. L’objectif primaire était de démontrer la non-infériorité du rabéprazole par 
comparaison au placebo en utilisant l’index de réactivité plaquettaire (test VASP) dans une 
population de volontaires sains bon répondeurs au clopidogrel. L’oméprazole a été utilisé 
comme contrôle positif. 
Méthodes. Étude croisée, randomisée, en trois périodes, menée chez 36 hommes volontaires 
sains recevant du clopidogrel (75mg/jour pendant 7 jours) avec du placebo, de l’omeprazole 
(20mg/jour) ou du rabeprazole (20mg/jour). L’effet anti-plaquettaire du clopidogrel et ses 
données pharmacocinétiques ont été mesurés au 7ème jour de traitement. Le seuil de non-
infériorité a été défini a priori comme une limite supérieure de l’intervalle de confiance à  90% 
<10% pour la différence entre la diminution de l’index de réactivité plaquettaire (test VASP) 
entre le placebo et le rabéprazole chez les bons répondeurs au clopidogrel.  
Résultats. Dans le groupe de bons répondeurs (inhibition du VASP PRI >30%), l’effet 
antiplaquettaire du clopidogrel était non inférieur à celui du placebo avec le rabéprazole 
(différence 3,4% (-1,7 ; 8,5)) contrairement à l’oméprazole (différence 7,5% (2,5 ; 12,6)). 
Toutefois, l’AUC0-24 et la Cmax du métabolite actif du clopidogrel étaient significativement 
diminuées avec l’oméprazole et le rabéprazole et les conditions de bioéquivalence n’étaient pas 
remplies, excepté pour l’AUC0-24 avec le rabéprazole. 
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Conclusion. L’interaction pharmacodynamique entre le rabéprazole et le clopidogrel n’a pas je 
même degré d’intensité que celle entre l’oméprazole et le clopidogrel.  Cependant, dans nos 
conditions expérimentales, l’interaction entre rabéprazole ou oméprazole et le clopidogrel 
n’était pas significative malgré une inhibition significative de la génération du métabolite actif 
du clopidogrel.  
Clinical Trial Registry n° NCT00989300 
 
Mots-clés: clopidogrel, CYP2C19, cytochrome P450, interactions médicamenteuses, inhibiteurs 
de pompes à protons, protéine VASP 
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INTRODUCTION 
Dual antiplatelet therapy with aspirin and clopidogrel is associated with a significant 
reduction in cardiovascular ischemic events after acute coronary syndromes or percutaneous 
coronary interventions and is recommended in US [1] and European [2] guidelines. Clopidogrel 
is an inactive prodrug which undergoes two oxidative steps involving multiple cytochrome P-
450 enzymes in its bioactivation to its pharmacologically active metabolite. Among them, 
CYP2C19, a cytochrome P-450 enzyme whose activity is genetically-determined, contributes 
predominantly to this bioactivation [3, 4] and modulates the antiplatelet and therapeutic 
response to clopidogrel.  Patients with loss of function polymorphism in the CYP2C19 gene are 
less responsive to clopidogrel [5, 6] although the importance of this phenomenon remains 
controversial [7-10] and may be limited to the risk of stent thrombosis [11]. 
Proton-pump inhibitors (PPIs) are recommended in patients treated with dual antiplatelet 
therapy who are at high risk of gastrointestinal bleeding [12]. PPIs are metabolized primarily via 
the cytochrome P-450 (CYP) 2C19 and CYP3A4 isoenzymes [13] and are competitive 
inhibitors of CYP2C19 activity [14]. However, the contribution of the CYP2C19 isoenzyme to 
PPI biotransformation, and to H. pylori eradication rates [15] and the potency for inhibition of 
CYP2C19 activity [14] varies among different PPIs. CYP2C19 activity appears to affect the 
response to omeprazole, esomeprazole and lansoprazole [16-18] and to be inhibited by these 
PPIs [14, 18]. This does not seem to be the case, at least not to the same extent, with 
pantoprazole [14, 19] and rabeprazole [14, 20]. 
Concerns of PPI and clopidogrel interaction were raised when omeprazole was found to 
inhibit the antiplatelet effect of clopidogrel in an in vivo study of 124 patients undergoing 
elective coronary stent implantation [21]. Several studies have suggested that omeprazole 
interacts with clopidogrel efficacy by inhibiting the formation of its active metabolite via 
CYP2C19 inhibition [22, 23]. Whether this occurs with all PPIs or even is of significant 
amplitude with omeprazole remains, however, a matter of debate [9, 24-29]. However it has 
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been recently demonstrated that generation of clopidogrel active metabolite and inhibition of 
platelet function were reduced less by the coadministration of dexlansoprazole or lansoprazole 
with clopidogrel than by the coadministration of esomeprazole or omeprazole [30].  
Since rabeprazole is a less potent CYP2C19 inhibitor than other PPIs [14], we performed 
a pharmacodynamic antiplatelet activity study of the interaction between standard recommended 
repeated doses of rabeprazole and clopidogrel in CYP2C19-genotyped healthy male subjects. 
Omeprazole and placebo were used as controls. Our primary objective was to demonstrate non-
inferiority of rabeprazole over placebo using the change in platelet reactivity index (ΔPRI%) in 
clopidogrel good responders as derived from the VAsodilator-Stimulated Phosphoprotein 
(VASP) assay as the primary endpoint. 
 
METHODS 
Study design 
This was a prospective, placebo- and active-controlled, open label, blinded evaluations, 
randomized 3-way crossover study. The study assessed the influence of rabeprazole (20 mg o.d. 
for 7 days) and omeprazole (20 mg o.d. for 7 days) on clopidogrel (75 mg o.d. for 7 days) 
antiplatelet effects and pharmacokinetics in 36 CYP2C19-genotyped non-smoking healthy 
Caucasian male subjects with normal basal platelet aggregation testing (> 50% aggregation to 1 
µg/mL collagen, 1 to 2 mmol/L arachidonic acid and 10µM adenosine diphosphate (ADP)), 
platelet count, complete blood count and prothrombin time. Subjects gave written informed 
consent to participate and to have CYP2C19 genotyping (but were not selected on their 
genotype) and the protocol was approved by the Committee for Protection of Human Subjects 
Île-de-France II and the French Medicine Agency. 
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Subjects were randomized based on a Latin square design to receive clopidogrel, 75 mg 
o.d. in the morning in the fasting state for 7 days during 3 study periods separated by a drug-free 
period of 2 to 3 weeks together with placebo, 20 mg of rabeprazole or 20 mg of omeprazole 
given at the same time as clopidogrel. Platelet function evaluation (pharmacodynamics) was 
performed on day 1 before dosing and on day 7 before and 4 hrs after the last intake of study 
drugs.  Pharmacokinetics of clopidogrel, its inactive carboxylic acid metabolite as well as the 
active metabolite was determined from blood samples taken before (H0) and at various times 
after administration of the last dose of clopidogrel with the concomitant drug (either placebo or 
PPI).  Additional blood samples for determination of omeprazole, 5-hydoxy-omeprazole, 
rabeprazole and rabeprazole-thioether plasma concentrations were taken 3 and 4 hrs post-dose 
on Day 7 to confirm proper exposure to PPIs. 
 
Pharmacodynamic evaluations 
The primary test to assess platelet function was based on the VASP-phosphorylation level 
measured on whole blood using a flow cytometric assay (Platelet VASP®, Diagnostica Stago, 
Biocytex, Asnières, France) and a FACScan flow cytometer (Becton Dickinson, Le Pont de 
Claix, France). Results were expressed as Platelet Reactivity Index (PRI%) calculated from the 
mean fluorescence intensity (MFI) of samples incubated with prostaglandin E1 (PGE1) alone or 
with both PGE1 and ADP simultaneously, using the following formula: (MFIPGE1– MFIPGE1+ADP 
/ MFIPGE1) x 100 as previously described [3]. This test, also referred to as the VASP index, is a 
test that specifically assesses P2Y12 receptor activity [31], the target of clopidogrel antiplatelet 
action and it is widely used for monitoring the responsiveness to clopidogrel [32, 33]. The 
percent change in PRI on study day 7 just before the last administration of study drugs relative 
to baseline, i.e. prior to drug administrations, percent change in ΔPRI (%) D7H0, was used as 
the primary study endpoint. ΔPRI (%) relative to Day1 was also calculated for Day 7 H4. 
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Platelet aggregation was also determined at the same time points as those of VASP-
phosphorylation level assessments with ADP-induced platelet optical aggregometry (Biopool, 
ADP 10 and 20µM) using platelet-rich plasma adjusted to 250 x 109/L. Inhibition of Platelet 
Aggregation (IPA%) induced by ADP was calculated as:[MPA(Day 1)–MPA(Day 7)/MPA(Day 
1) x 100], where MPA is the maximal platelet aggregation induced by ADP. Platelet 
aggregation tests were performed on a TA-8V optical platelet aggregometer (Soderel Medical, 
Heillecourt, France) within 3 hours from sampling in all subjects. 
Pharmacodynamic evaluations were performed blind to the study period and to CYP2C19 
genotype. 
 
Pharmacokinetic evaluations 
Blood samples for clopidogrel assay were collected in 6ml EDTA vials stored at +4°C to 
which 38µl of 2-Bromo-3′-methoxyacetophenone (500mM in acetonitrile) were added within 30 
sec of sampling to stabilize the active metabolite. Blood samples were centrifuged at +4°C 
within 30min and stored at −80 °C until assay. Clopidogrel, clopidogrel carboxylic acid, 
clopidogrel active metabolite, omeprazole, 5-hydroxy-omeprazole, rabeprazole and rabeprazole-
thioether, were extracted from plasma on solid phase OASIS HLB cartridge (10mg/1ml, Waters 
SAS, Milford USA). Chromatographic separation and detection of all compounds was 
performed on YMC–UltraHT Pro C18 analytical column (YMC, Dinslaken, Germany) using a 
ultra high performance liquid chromatography coupled to tandem mass spectrometry system 
(UPLC-Acquity-TQD Waters SAS, Milford, USA). Limits of quantification were 0.1ng/ml for 
clopidogrel and clopidogrel active metabolite, 5ng/ml for rabeprazole and rabeprazole-thioether, 
10ng/ml for clopidogrel carboxylic acid, 50ng/ml for omeprazole and 5-hydroxy-omeprazole. 
Pharmacokinetic parameter values were calculated using WinNonlin Professional 
Version 5.2, or higher, (Pharsight Corp., Mountain View, California). Maximum plasma 
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concentration (Cmax) and the time of its occurrence (Tmax) were obtained from observed values. 
The area under the concentration-time curve (AUC) in the sampled matrix during a dosing 
interval was calculated by linear up/log down trapezoidal summation. Apparent terminal rate 
constant (λz) after multiple dosing (1/h), was determined by linear regression of the terminal 
points of the log linear concentration time curve. Apparent terminal half-life after multiple 
dosing (h) was determined as (ln2/λz). 
 
CYP2C19 genotyping and activity 
The loss-of-function CYP2C19 variants *2 (rs4244285) and *3 (rs4986893) were tested 
using PCR-based specific probe hybridization and single base extension. 681G>A and 636G>A 
comprise the two common reduced functional variants CYP2C19*2 and CYP2C19*3, 
respectively. Subjects with the CYP2C19*1/*1 genotype were designated as CYP2C19 
extensive metabolizer (EM) subjects.  
The molar omeprazole/5-hydroxy-omeprazole metabolic ratio in plasma samples at 3hrs 
was calculated as an index of CYP2C19 activity [34-36].  In one EM subject, this ratio was 
calculated from the blood sample taken at 4 hrs because 5-hydroxy-omeprazole was not 
detectable at 3 hrs. 
 
Statistical analyses 
Sample size was calculated with the assumption that approximately 66% of subjects 
would be good antiplatelet responders defined as subjects in whom the VASP index on study 
day 7 relative to study day 1 would decrease by at least 30% with an expected intra-subject 
standard deviation of differences in ΔPRI of ≤14% [37] or a PRI value at day 7 below a cut-off 
value of 60 %, as recently proposed for clopidogrel 75 mg daily maintenance dose [38]. With 
these assumptions, 36 subjects were sufficient to conclude for non-inferiority of rabeprazole to 
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placebo with 10% ΔPRI as the limit of non inferiority with greater than 95% power when true 
difference in treatment means is equal to 2%. Pharmacodynamic analyses were first performed 
on good antiplatelet responders as defined above, then on all 36 subjects.  
Mixed effect models were fitted to the ΔPRI% data as the dependent variable, and 
sequence, treatment and period as factors and subject as a random effect. Ninety percent 
confidence intervals (CI) were calculated for the difference in means between rabeprazole 
versus placebo. Non-inferiority was concluded if the upper limit of the 90% CI fell below 10%. 
This non-inferiority limit was chosen because it represents the difference between omeprazole 
and placebo reported by Gilard et al. [21] (10.7% in absolute value, 13.4% in relative value) 
which prompted the FDA’s warning on PPIs interaction with clopidogrel. 
Additional post-hoc analyses were performed to compare the change in VASP index on 
study day 7 relative to study day 1 with omeprazole and rabeprazole relative to placebo using 
Wilcoxon signed ranks test in good antiplatelet responders. Post-hoc correlations analyses were 
performed using Pearson's correlation. 
A linear mixed effects model suitable for 3-way crossover design was fit to log-
transformed pharmacokinetic parameters and 90% CI for the ratio of the mean pharmacokinetic 
parameters of clopidogrel were constructed using least-square means and intra-subject variance 
from the model. The above analysis was performed for clopidogrel active metabolite and 
clopidogrel major carboxylic acid metabolite. Bioequivalence was considered as demonstrated 
if the 90% CI of the ratios for AUC0-24 and Cmax between the placebo and PPI study periods 
fell in the range 80 – 125%. 
 
RESULTS 
Thirty six subjects completed the three study periods. Mean age, body weight and body 
mass index were 33.6±7.9 yrs, 74.1±8.7 kg and 23.6±2.3 kg/m², respectively. Of these 36 
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subjects, 23 were CYP2C19*1/*1 EMs, 12 were heterozygous CYP2C19*1/*2 and one was a 
poor metabolizer with the CYP2C19*2/*2 genotype. 
 
Platelet function assays: 
Baseline VASP Index before administration of clopidogrel was not significantly different 
across study periods (p=0.60). As expected, there was considerable inter-individual variability 
in platelet function inhibition as measured by use of the VASP index (VASP ΔPRI%) on day 7 
of the clopidogrel plus placebo study period prior to last drug administration (D7H0) (figure 1). 
The decrease in VASP index was <30% in 18 subjects while the other 18 subjects were 
classified as good clopidogrel responders (change of VASP index >–30%). Table 1 shows the 
results of platelet aggregation studies on day 7 (D7) of each study period before (H0) and 4hrs 
(H4) after administration of the last dose of clopidogrel together with placebo, omeprazole and 
rabeprazole. 
In good clopidogrel responders as evaluated by VASP assay, the upper limit of the 90% 
CI non-inferiority threshold of 10% was crossed during co-prescription of omeprazole but not 
during co-prescription of rabeprazole at D7H0 and D7H4. Therefore, in this pre-defined group 
of subjects in whom a significant antiplatelet activity was present during administration of 
clopidogrel with placebo, the antiplatelet effect of clopidogrel during co-administration of 
rabeprazole was non-inferior to placebo whereas this was not the case during omeprazole co-
administration. In this group, the increase of VASP reactivity index relative to placebo did not 
differ significantly during rabeprazole and during omeprazole (p=0.067, figure 2).. However, 
the change in VASP index from placebo was statistically significant during omeprazole 
(p=0.017) but not during rabeprazole (p=0.26) at D7H0 and D7H4 (p<0.009 and p=0.20, 
respectively) (Table 1) 
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When considering the entire population of 36 subjects, VASP index at D7H0 and D7H4 was not 
significantly altered by co-administration of omeprazole or rabeprazole. The increase of VASP 
index at D7H4 with omeprazole did not reach statistical significance (p=0.056). Between-period 
differences were less consistent when considering inhibition of platelet aggregation (IPA%) 
induced by ADP (table 1). The 10% non-inferiority threshold was crossed in all subjects for 
both omeprazole and rabeprazole only in the presence of ADP 10µM.  
CYP2C19 genotype influenced the antiplatelet effects of clopidogrel. Compared with 
subjects with the CYP2C19*1/*2 genotype (n=12), EM subjects (n=23) had more antiplatelet 
effect as assessed by the change in VASP index at D7H0 during placebo (-39.3±0.20% in 
CYP2C19*1/*1 vs. -22±0.15% in CYP2C19*1/*2; p<0.015). Among the 23 EM subjects, 15 
were good antiplatelet responders. One subject became non-responder with omeprazole and 
none with rabeprazole (figure 3). Among the 12 subjects with the CYP2C19*1/*2 genotype, 
only 3 were good antiplatelet responders during administration of clopidogrel with placebo. One 
subject became non-responder with both rabeprazole and omeprazole (figure 3). 
 
Clopidogrel disposition kinetics: 
Table 2 shows the main pharmacokinetic parameters for clopidogrel active metabolite in 
all subjects. We also analyzed pharmacokinetics parameters in EM subjects homozygous for 
CYP2C19*1*1. Figure 4 shows the plasma concentration vs. time profile of clopidogrel active 
metabolite in all subjects. 
In the entire population, despite a significant fall compared to placebo, the AUC0-24 of 
clopidogrel active metabolite during rabeprazole co-administration remained within the 
bioequivalence limits relative to the placebo study period. This was not the case during 
omeprazole co-administration. Bioequivalence was not met for Cmax during administration of 
both PPIs. In EM subjects, bioequivalence was not met for any of the measured parameters 
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during both omeprazole and rabeprazole co-administration. Mean Tmax was 0.67hr in the 3 
study groups. 
The AUC0-24 and apparent elimination half-life of clopidogrel and its main carboxylic 
acid metabolite remained within the bioequivalence range during both omeprazole and 
rabeprazole co-administration (data not shown). Other parameters which were not bioequivalent 
were: Cmax of clopidogrel during the rabeprazole study period (ratio of 85.1, 90% CI: 75.1–
98.0), Cmax of carboxylic acid metabolite during rabeprazole (ratio of 82.0, 90% CI: 72.2–93.2) 
and during omeprazole (ratio of 83.3, 90% CI: 73.3–94.6) co-administration. 
In the 23 subjects who were CYP2C19 EMs, AUC0-24 of clopidogrel active metabolite 
decreased significantly during co-administration of omeprazole and rabeprazole (figure 5). 
 
Regression analyses: 
Platelet reactivity (VASP PRI) at D7H0 negatively correlated with clopidogrel active 
metabolite AUC0-24 during placebo (r²=0.32; n=36; p<0.001), rabeprazole (r²=0.30; n=36; 
p<0.001) and omeprazole (r²=0.18; n=36; p<0.007) co-administration. The change of VASP 
Δ PRI at D7H0 from placebo during each PPI study period positively correlated with the change 
of clopidogrel active metabolite AUC0-24 during co-administration of the corresponding drug, 
rabeprazole (r²=0.11; n=36; p<0.025) or omeprazole (r²=0.11; n=36; p<0.027). 
Omeprazole metabolic ratio could not be determined in one EM subject. The change in 
platelet inhibition (VASP Δ PRI) at D7H0 during the placebo period and the change of platelet 
aggregation (IPA%) induced by ADP 10µM (but not 20µM) at D7H0 positively correlated with 
the omeprazole metabolic ratio (r²=0.19; n=35; p<0.006 and r²=0.17; n=35; p<0.009, 
respectively) a higher metabolic ratio, i.e. less CYP2C19 activity, being associated with less 
antiplatelet effect. No significant correlation was found between the change of VASP index or 
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the change in AUC of clopidogrel active metabolite during omeprazole or rabeprazole periods 
and CYP2C19 activity as assessed by use of the omeprazole metabolic ratio. 
There was no correlation between omeprazole plasma concentration at 3hrs (mean, SD: 
665±576ng/ml) or rabeprazole (mean, SD: 351±233ng/ml) or rabeprazole-thioether (mean, SD: 
129±85ng/ml) plasma concentration at 4hrs and the change in VASP Δ PRI during the 
corresponding PPI combination therapy. 
The fall in clopidogrel active metabolite Cmax and AUC0-24 during rabeprazole and 
omeprazole were correlated (r²=0.56; n=36; p<0.001 in both cases) and the slopes of these 
relationships did not significantly differ from unity. 
 
DISCUSSION 
This randomized study, cross over study was designed to analyze the potential interaction 
between clopidogrel and rabeprazole, omeprazole being used as a putative positive control. It 
was conducted in healthy male volunteers, thus eliminating potential confounding factors, 
including smoking, noncompliance and other medications.  
Since an inhibitory interaction is not expected to occur in subjects who do not have an 
adequate response in the absence of inhibitor, the predefined group of VASP antiplatelet good 
responders was chosen to examine the pharmacodynamic interactions between rabeprazole and 
clopidogrel. VASP index is considered as a specific test to evaluate P2Y12 inhibition compared 
to light-transmission aggregometry to predict outcome during dual antiplatelet therapy although 
both tests have a predictive value [31, 33, 39, 40]. In the group of good VASP antiplatelet 
responders, clopidogrel antiplatelet effect remained non-inferior to placebo at D7H0 and D7H4 
during rabeprazole co-administration whereas it crossed the limit of non-inferiority during 
omeprazole co-administration. Therefore, from a pharmacodynamic point of view, in subjects in 
whom clopidogrel elicits a marked antiplatelet effect, inhibition of clopidogrel antiplatelet 
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action is minimal with rabeprazole whereas a statistically significant reversal of clopidogrel 
effects is observed with omeprazole. 
However, when using aggregometry, a test less specific of P2Y12 but that reflects the 
global platelet function, inhibition of platelet aggregation induced by ADP 10µM significantly 
decreased with both omeprazole and rabeprazole in the entire population. These results are in 
line with PK analysis, showing a decreased exposure to clopidogrel active metabolite with both 
PPIs. AUC0-24 and Cmax of active clopidogrel metabolite significantly decreased with both 
omeprazole and rabeprazole and conditions of bioequivalence were not met, except for AUC0-24 
with rabeprazole. This discrepancy between pharmacokinetic and pharmacodynamic parameters 
(VASP) changes was also found in a drug interaction study which examined the influence of 
pantoprazole (80mg/day) on clopidogrel antiplatelet effects and exposure to its active metabolite 
[19]. In this study, no significant change in VASP index (but significant changes in ADP 5µM-
induced maximum platelet aggregation) was found despite a statistically significant decrease in 
clopidogrel active metabolite AUC0-24 and Cmax with pantoprazole of the same order of 
magnitude as what was found in our study. Greater decreases of exposure to clopidogrel active 
metabolite were found with high dose omeprazole (80mg/day) in the study by Angiollilo et al. 
[19] and were associated with significant inhibition of VASP and ADP-induced platelet 
aggregation. In our study the change of VASP index with PPIs was weakly associated (r²=0.11) 
with the change of clopidogrel active metabolite exposure produced by omeprazole and 
rabeprazole although the association between VASP index and clopidogrel active metabolite 
AUC0-24 was stronger (r²=0.32) during administration of clopidogrel with placebo. Taken 
together, these results suggest that a certain extent of pharmacokinetic interaction on clopidogrel 
active metabolite is necessary to produce a significant pharmacodynamic interaction. This could 
explain why the amplitude of the pharmacodynamic interaction we found with omeprazole was 
limited in size. 
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As expected, [22, 23] CYP2C19 genotype and activity influenced clopidogrel antiplatelet 
activity in the absence of PPI with greater inhibition of platelet aggregation in homozygous EM 
subjects compared to subjects with at least one non-functional CYP2C19 allele. Also, during the 
placebo study period, clopidogrel-induced change of VASP index and of platelet aggregation 
induced by 10µM (but not 20µM) ADP correlated with CYP2C19 activity as assessed by use of 
the omeprazole metabolic ratio. However, the association was weak with only about 18% of 
antiplatelet effect explained by the omeprazole metabolic ratio. During PPI administrations, no 
significant correlation was found between the change of VASP index or the change in AUC of 
clopidogrel active metabolite and CYP2C19 activity as assessed by the omeprazole metabolic 
ratio. Such an absence of association by regression analysis raises the question of the role of 
CYP2C19 inhibition in explaining our findings. Rabeprazole is mainly metabolized by non-
enzymatic reduction to rabeprazole-thioether [41] and is a less potent inhibitor of CYP2C19 
than omeprazole [14, 42, 43]. This may explain the fact that rabeprazole had less effects than 
omeprazole on the clopidogrel-induced change of VASP index although the study was not 
powered to test the statistical significance of this difference. However it does not explain the 
similarity of the pharmacokinetic interaction on clopidogrel active metabolite with both PPIs. In 
this respect, pantoprazole [19] and rabeprazole appear to have comparable profiles. Also, 
rabeprazole-thioether, the main circulating metabolite of rabeprazole, is a CYP2C19 inhibitor 
[14] and could have contributed to the observed effects. Finally, CYP2C19 is not the only 
cytochrome P-450 which contributes to the bioactivation of clopidogrel to its active metabolite 
[4]. CYP2C19 contributes to the first step of clopidogrel metabolism to its 2-oxo unstable 
metabolite for 45% while CYP1A2 and CYP2B6 contribute for 36% and 19%, respectively. 
CYP2C19 contributes to the final step of clopidogrel active metabolite formation from 2-
oxoclopidogrel for only 20% while CYP3A4, CYP2B6 and CYP2C9 contribute for 40%, 33% 
and 7%, respectively [4]. It is therefore conceivable that non CYP2C19-mediated mechanisms 
may contribute to the interaction between PPIs and clopidogrel. 
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For uniformity, our study included only young male volunteers, a population which does 
not reflect the diversity of patients with ischemic heart disease who usually receive dual 
antiplatelet therapy and an initial loading dose of clopidogrel. In the target population, 
clopidogrel is usually prescribed with aspirin and it has been suggested that inhibition of 
antiplatelet effect may result from an interaction of PPIs with aspirin absorption [44, 45] 
independently from the interaction with clopidogrel [46, 47]. Inhibition of clopidogrel 
absorption by PPIs is unlikely to occur since clopidogrel is a weak base which is not absorbed 
from the stomach, in contrast to aspirin. To our knowledge only one study compared the effects 
of omeprazole and rabeprazole on the antiplatelet action of clopidogrel in patients on dual 
antiplatelet therapy [48]. In this open-labeled study in a limited number of patients, both 
omeprazole and rabeprazole decreased the effects of clopidogrel on platelet aggregation induced 
by 10µM ADP. However, the authors acknowledged that their study was not placebo-controlled 
and did not have the power to detect a difference between omeprazole and rabeprazole. Another 
recent study reported on the interaction between a single 300 mg dose of clopidogrel and 
rabeprazole (20mg) and did not find an interaction [49]. Our study, despite its limitations 
indicated above, suggests that the interaction between rabeprazole and clopidogrel is likely to be 
less pronounced than the interaction between omeprazole and clopidogrel in patients with heart 
disease. It also shows that the interaction with omeprazole is of small amplitude when the 
standard therapeutic dose of 20mg/day is used. Under our experimental conditions and PPIs 
doses, there was no significant pharmacodynamic interaction between rabeprazole or 
omeprazole and clopidogrel despite a significant decrease in the formation of clopidogrel active 
metabolite. This is consistent with a previous study with pantoprazole [19] and suggests that 
there is a threshold of decreased clopidogrel active metabolite formation which is required to 
produce a pharmacodynamic interaction. 
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Figure Legends 
 
Figure 1:  Change of VASP platelet reactivity index (PRI) at trough on day 7 of 
clopidogrel 75 mg o.d. in the presence of placebo in 36 healthy subjects.  
Subjects in whom the VASP index on Day 7 relative to Day 1 was decreased by at 
least 30% were defined as good antiplatelet responders. 
 
Figure 2:  Change of VASP platelet reactivity index (PRI) on day 7 at trough of 
clopidogrel 75 mg o.d. during co-administration of rabeprazole and 
omeprazole in 18 good antiplatelet responders. Each box plots represents 
interquartile range with mean (horizontal line in the box) and median (dot in the 
box) and whiskers represent the 5 - 95 percentiles. p=0.067 
 
Figure 3: Change of VASP platelet reactivity index (PRI) at trough on day 7 of 
clopidogrel 75 mg o.d. in the presence of placebo, rabeprazole and omeprazole 
in 36 healthy subjects according to CYP2C19 genotypes. 
 
Figure 4:  Mean (SD) plasma concentration of clopidogrel active metabolite as a function 
of time on day 7 of clopidogrel 75 mg o.d. in the presence of placebo, 
rabeprazole and omeprazole in 36 healthy subjects. 
 
Figure 5:  Area under plasma concentration-time curve from 0 to 24 hours of clopidogrel 
active metabolite on day 7 of clopidogrel 75 mg o.d. in the presence of placebo, 
rabeprazole and omeprazole in 36 healthy subjects according to CYP2C19 
genotypes.  * p<0.001 
 
 29
Table 1:  Antiplatelet effects of clopidogrel 75 mg o.d. for 7 days in the presence of 
placebo, omeprazole and rabeprazole. 
      Least Square Pairwise Comparisons 
  Treatment N 
Mean 
(%) 95% CI Pair 
Difference 
(%) 90% CI 
p-
value*
VASP ΔPRI (%)         
Good VASP Antiplatelet responders      
Day 7 / Hour 0 RABE 18 -47.3 (-52.5; -42.1) RABE/OME -4.1 (-9.2; 1.0) 0.18 
     RABE/PLBO 3.4 (-1.7; 8.5) 0.26 
 OME 18 -43.2 (-48.4; -38.0) OME/PLBO 7.5 (2.5; 12.6) 0.017 
 PBO 18 -50.7 (-55.9; -45.6)     
         
Day 7 / Hour 4 RABE 18 -56.2 (-62.5; -49.9) RABE/OME -4.9 (-10.5; -0.8) 0.15 
     RABE/PLBO 4.4 (-1.2; 9.9) 0.2 
 OME 18 -51.3 (-57.6; -45.1) OME/PLBO 9.2 (3.6; 14.8) 0.0087
 PBO 18 -60.3 (-66.8; -54.3)     
         
All subjects         
Day 7 / Hour 0 RABE 36 -32.1 (-38.8; -25.5) RABE/OME -1.6 (-5.1; 1.8) 0.44 
     RABE/PLBO 0.4 (-3.1; 3.8) 0.85 
 OME 36 -30.5 (-37.5; -23.9) OME/PLBO 2 (-1.5; 5.5) 0.34 
 PBO 36 -32.5 (-39.2; -25.9)     
         
Day 7 / Hour 4 RABE 36 -39.8 (-47.4; -32.1) RABE/OME -3.7 (-7.2; -0.1) 0.089 
     RABE/PLBO 0.5 (-3.1; 4.0) 0.82 
 OME 36 -36.1 (-43.8; -28.5) OME/PLBO 4.2 (0.6; 7.7) 0.056 
 PBO 36 -40.3 (-47.9; -32.6)     
         
         
Inhibition of platelet aggregation (IPA) 
induced by ADP Day 7 / Hour 0       
All subjects         
ADP 20µM RABE 36 39.4 (32.4; 46.4) RABE/OME 4.3 (-0.1; 8.8) 0.11 
     RABE/PLBO -0.8 (-5.3; 3.7) 0.77 
 OME 36 35.1 (28.1; 42.1) OME/PLBO -5.1 (-9.6; -0.6) 0.063 
 PBO 35 40.2 (33.1; 47.2)     
         
ADP 10µM RABE 36 39.8 (32.7; 46.9) RABE/OME 0.6 (-4.7; 5.8) 0.86 
     RABE/PLBO -6.3 (-11.6; -1.1) <0.05 
 OME 36 39.2 (32.1; 46.3) OME/PLBO -6.9 (-12.2; -1.6) 0.033 
 PBO 35 46.1 (39.0; 53.3)     
         
VASP: VAsodilator-Stimulated Phosphoprotein; ΔPRI: Change in Platelet Reactivity Index; 
ADP: adenosine diphosphate; IPA: Inhibition of Platelet Aggregation; CI: Confidence Interval, 
RABE: rabeprazole; OME: omeprazole; PLBO: placebo; Good Antiplatelet Responders were 
defined as subjects in whom the VASP index on Day 7 relative to Day 1 was decreased by at 
least 30%. * p values for equality of means. 
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Table 2: Pharmacokinetics of Clopidogrel Active Metabolite on day 7 of clopidogrel 
75 mg o.d. in the presence of placebo, omeprazole and rabeprazole. 
      
Geometric 
Least Square 
Pairwise Comparisons 
Parameter (unit) Treatment N Mean 95% CI Pair 
Ratio 
(%) 
90% CI p-value 
         
All subjects         
AUC0-24 (ngh/mL) RABE 36 26.6 (23.1 - 30.6) RABE/OME 108.1 (100.0 - 116.9) 0.10 
                         RABE/PLBO 88.4 (81.7 - 95.6)  0.01 
 OME 36 24.6 (21.4 - 28.3) OME/PLBO 81.7 (75.6 - 88.4)  <0.0001
 PLBO 36 30.1 (26.2 - 34.6)                                
                                                        
Cmax (ng/mL) RABE 36 15.1 (12.5 - 18.1) RABE/OME 105.8 (90.6 - 123.6) 0.54 
                         RABE/PLBO 72.1 (61.7 - 84.2)  <0.001 
 OME 36 14.3 (11.9 - 17.1) OME/PLBO 68.1 (58.3 - 79.5)  0.0001 
 PLBO 36 20.9 (17.4 - 25.2)                                
                                                        
t1/2 (h) RABE 19 4.5 (2.7 - 7.7) RABE/OME 91.5 (56.8 - 147.4) 0.75 
                         RABE/PLBO 105.3 (65.3 - 169.5) 0.86 
 OME 19 5.0 (2.9 - 8.4) OME/PLBO 115.0 (71.4 - 185.3) 0.62 
 PLBO 19 4.3 (2.6 - 7.3)     
                    
CYP2C19 *1/*1       
AUC0-24 (ngh/mL) RABE 23 29.8 (25.7 - 34.5) RABE/OME 107.1 (97.8 - 117.3) 0.21 
                        RABE/PLBO 82.3 (75.1 - 90.2)  0.0009 
 OME 23 27.8 (24.0 - 32.2) OME/PLBO 76.8 (70.1 - 84.2)  <0.0001
 PLBO 23 36.2 (31.3 - 41.9)                               
                                                      
Cmax (ng/mL) RABE 23 16.7 (13.3 - 21.1) RABE/OME 104.1 (86.6 - 125.3) 0.72 
                        RABE/PLBO 66.8 (55.4 - 80.5)  0.0008 
 OME 23 16.1 (12.8 - 20.3) OME/PLBO 64.1 (53.3 - 77.2)  0.0002 
 PLBO 23 25.1 (19.9 - 31.6)                               
                                                      
t1/2 (h) RABE 10 6.4 (3.3 - 12.6) RABE/OME 126.5 (62.5 - 256.1) 0.57 
                        RABE/PLBO 75.8 (37.0 - 155.4) 0.51 
 OME 10 5.1 (2.5 - 10.1) OME/PLBO 59.9 (28.1 - 127.5) 0.25 
  PLBO 10 8.5 (4.2 - 17.0)         
 
AUC0-24: area under plasma concentration-time curve from 0 to 24 hours; Cmax: Maximum 
observed plasma concentration; t1/2: apparent elimination half-life; CI: Confidence Interval, 
RABE: rabeprazole; OME: omeprazole; PLBO: placebo. 
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Figure 1:  Change of VASP platelet reactivity index (PRI) at trough on day 7 of 
clopidogrel 75 mg o.d. in the presence of placebo in 36 healthy subjects.  
Subjects in whom the VASP index on Day 7 relative to Day 1 was decreased by at 
least 30% were defined as good antiplatelet responders. 
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 Figure 2:  Change of VASP platelet reactivity index (PRI) on day 7 at trough of 
clopidogrel 75 mg o.d. during co-administration of rabeprazole and 
omeprazole in 18 good antiplatelet responders. Each box plots represents 
interquartile range with mean (horizontal line in the box) and median (dot in the 
box) and whiskers represent the 5 - 95 percentiles. p=0.067 
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Figure 3: Change of VASP platelet reactivity index (PRI) at trough on day 7 of 
clopidogrel 75 mg o.d. in the presence of placebo, rabeprazole and omeprazole 
in 36 healthy subjects according to CYP2C19 genotypes. 
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Figure 4:  Mean (SD) plasma concentration of clopidogrel active metabolite as a function 
of time on day 7 of clopidogrel 75 mg o.d. in the presence of placebo, 
rabeprazole and omeprazole in 36 healthy subjects. 
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 Figure 5:  Area under plasma concentration-time curve from 0 to 24 hours of clopidogrel 
active metabolite on day 7 of clopidogrel 75 mg o.d. in the presence of placebo, 
rabeprazole and omeprazole in 36 healthy subjects according to CYP2C19 
genotypes.  * p<0.001 
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